Söndag 27 April | 02:19:12 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-13 08:50 Bokslutskommuniké 2025
2025-08-22 08:50 Kvartalsrapport 2025-Q2
2025-06-18 N/A X-dag ordinarie utdelning COMBI 0.00 SEK
2025-06-17 N/A Årsstämma
2025-02-20 - Extra Bolagsstämma 2024
2025-02-14 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning COMBI 0.00 SEK
2024-05-23 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning COMBI 0.00 SEK
2023-05-25 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning COMBI 0.00 SEK
2022-05-19 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-06-07 - Split COMBI 20:1
2021-05-26 - X-dag ordinarie utdelning COMBI 0.00 SEK
2021-05-25 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-30 - X-dag ordinarie utdelning COMBI 0.00 SEK
2020-06-29 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-17 - Kvartalsrapport 2019-Q1
2019-05-16 - Årsstämma
2019-05-15 - X-dag ordinarie utdelning COMBI 0.00 SEK
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning COMBI 0.00 SEK
2018-05-03 - Årsstämma
2018-05-03 - Kvartalsrapport 2018-Q1
2018-01-29 - Bokslutskommuniké 2017
2017-11-01 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2
2017-05-18 - Kvartalsrapport 2017-Q1
2017-05-10 - X-dag ordinarie utdelning COMBI 0.00 SEK
2017-05-09 - Årsstämma
2017-01-31 - Bokslutskommuniké 2016
2017-01-26 - Extra Bolagsstämma 2017
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-19 - Kvartalsrapport 2016-Q1
2016-04-05 - X-dag ordinarie utdelning COMBI 0.00 SEK
2016-04-04 - Årsstämma
2016-02-18 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
CombiGenes vision är att ge patienter som drabbats av svåra sjukdomar möjlighet till ett bättre liv genom genterapi och andra former av avancerade behandlingar. Bolagets verksamhet har tre fokusområden: inlicensiering av nya tillgångar, utveckling av dessa tillgångar till proof-of-concept samt utlicensiering av tillgångarna till en strategisk partner för fortsatt utveckling och kommersialisering. CombiGene has sitt säte i Stockholm.
2022-05-19 11:40:00

The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ) (“CombiGene”) on 19 May 2022 in Stockholm.
 
Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement, balance sheet and consolidated balance sheet for the financial year 2021. The board members and the CEO were discharged from liability for the financial year 2021.
 
Allocation of profit or loss
The AGM resolved, in accordance with the board of directors’ proposal, that no dividend shall be paid for 2021 and that the results of the company shall be carried forward.
 
Board of directors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Peter Nilsson, Bert Junno, Jonas Ekblom, Per Lundin and Gunilla Lundmark as board members. Bert Junno was re-elected as the chairman of the board of directors. The AGM re-elected the audit firm Mazars AB as auditor.
 
The AGM further resolved, in accordance with the nomination committee’s proposal, on remuneration to the board of directors and that remuneration to the auditor shall be paid in accordance with approved invoicing.
 
Nomination committee for the next AGM
The AGM resolved, in accordance with the nomination committee’s proposal, on instruction for the nomination committee.
 
Authorisation to issue new shares, warrants or convertibles
The AGM resolved, in accordance with the board of directors’ proposal, to authorize the board of directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the company’s share capital by issuing new shares, warrants or convertibles. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The total number of shares that may be issued, or, as regards issue of convertibles or warrants, issued by conversion or exercise, under the authorisation shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association.
  
LTI 2022
The AGM resolved, in accordance with the board of directors’ proposal, on the implementation of LTI 2022, directed issue of 900,000 warrants, transfer of the warrants to participants in LTI 2022 and transfer of warrants to cover costs for LTI 2022 and authorisation to enter into swap agreement. A more detailed description of LTI 2022 can be found in the notice convening the Annual General Meeting 2022.